Teachers Advisors LLC Sells 517,679 Shares of Celgene (CELG)

Teachers Advisors LLC reduced its stake in shares of Celgene (NASDAQ:CELG) by 22.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,820,861 shares of the biopharmaceutical company’s stock after selling 517,679 shares during the period. Teachers Advisors LLC’s holdings in Celgene were worth $190,025,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of CELG. Ark Investment Management LLC raised its position in shares of Celgene by 78.7% during the 2nd quarter. Ark Investment Management LLC now owns 1,599 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 704 shares during the period. Scotia Capital Inc. raised its position in shares of Celgene by 21.0% during the 2nd quarter. Scotia Capital Inc. now owns 69,457 shares of the biopharmaceutical company’s stock valued at $9,020,000 after buying an additional 12,058 shares during the period. Linscomb & Williams Inc. raised its position in shares of Celgene by 1.0% during the 2nd quarter. Linscomb & Williams Inc. now owns 3,813 shares of the biopharmaceutical company’s stock valued at $495,000 after buying an additional 36 shares during the period. Chiron Investment Management LLC raised its position in shares of Celgene by 38.4% during the 2nd quarter. Chiron Investment Management LLC now owns 131,800 shares of the biopharmaceutical company’s stock valued at $17,117,000 after buying an additional 36,600 shares during the period. Finally, Cypress Capital Group raised its position in shares of Celgene by 12.6% during the 2nd quarter. Cypress Capital Group now owns 39,742 shares of the biopharmaceutical company’s stock valued at $5,162,000 after buying an additional 4,450 shares during the period. Institutional investors and hedge funds own 78.53% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other news, Director Ernest Mario sold 13,370 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $94.49, for a total transaction of $1,263,331.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $95.99, for a total value of $887,907.50. Following the sale, the director now directly owns 94,801 shares in the company, valued at approximately $9,099,947.99. The disclosure for this sale can be found here. Insiders have sold 41,120 shares of company stock worth $3,879,509 in the last ninety days. Corporate insiders own 0.95% of the company’s stock.

Celgene stock opened at $90.54 on Tuesday. Celgene has a twelve month low of $84.25 and a twelve month high of $147.17. The company has a debt-to-equity ratio of 2.29, a quick ratio of 4.80 and a current ratio of 4.99. The firm has a market cap of $67,244.50, a PE ratio of 13.03, a P/E/G ratio of 0.60 and a beta of 1.48.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business had revenue of $3.48 billion for the quarter, compared to analyst estimates of $3.46 billion. During the same quarter in the prior year, the company earned $1.61 earnings per share. The company’s revenue was up 16.9% on a year-over-year basis. analysts predict that Celgene will post 7.66 EPS for the current year.

Celgene announced that its board has authorized a share repurchase program on Wednesday, February 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Several analysts have recently commented on the stock. Morgan Stanley reaffirmed an “equal weight” rating and set a $93.00 price target on shares of Celgene in a research report on Friday. ValuEngine lowered shares of Celgene from a “hold” rating to a “sell” rating in a research report on Thursday, April 12th. Cantor Fitzgerald set a $112.00 price target on shares of Celgene and gave the company a “hold” rating in a research report on Monday, April 2nd. Leerink Swann set a $123.00 price target on shares of Celgene and gave the company a “buy” rating in a research report on Wednesday, March 28th. Finally, Zacks Investment Research lowered Celgene from a “hold” rating to a “sell” rating in a research report on Tuesday, March 27th. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. Celgene has a consensus rating of “Hold” and an average price target of $126.95.

TRADEMARK VIOLATION WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/17/teachers-advisors-llc-sells-517679-shares-of-celgene-celg.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply